When NAbs titers measured by neutralization assays correlate with the severity of SARS-CoV-2 infection, it has been established that patients with severe infections had a more robust NAbs response, and the NAbs lasted longer. By comparison, asymptomatic patients have low levels of specific IgG, long persistence of viral RNA, and did not display a strong antibody response. Therefore, asymptomatic patients may have a risk of breakthrough infection.
